Loading data for HCM — first visit, this takes a few seconds.

알림

HUTCHMED (China) Limited (HCM)

NasdaqGS: HCM · 실시간 가격 · USD

12.53

-0.11 (-0.87%)

종가 기준: Aug 19, 2026, 8:00 PM

12.59

+0.00%

애프터마켓: 4:10 PM

-0.87% (1D)

데이터 없음

매수호가	8.96
시가총액	2.19B
매출 (ttm)	549.12M
순이익 (ttm)	17.88M
베타	0.44
EPS (ttm)	0.1
P/E (ttm)	125.9
선행 P/E	51.64
P/B (ttm)	1.74
P/S (ttm)	3.99
Earnings Date	Jul 30, 2017

매도호가	15.74
거래량	28,244
평균 거래량 (20일)	57,191
시가	12.30
전일 종가	12.64
일중 범위	12.30 - 12.53
52주 범위	9.77 - 18.30
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

HCM 소개

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-C...

섹터 Healthcare

IPO 일자 Mar 16, 2016

직원 수 1,790

상장 거래소 NasdaqGS

티커 HCM

웹사이트 https://www.hutch-med.com

전체 기업 정보

재무 실적

2025년 HUTCHMED (China)의 매출은 548.51M로, 전년 630.2M 대비 -12.96% 감소했습니다. 순이익은 456.91M로, 1,111.03% 증가했습니다.

재무제표

어닝 서프라이즈

HUTCHMED (China)가 Mar 2, 2022에 분기 실적을 발표했습니다:

매출 n/a 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.03 예상치 상회 0.10, 및 0.00% 전년 대비 성장.

다음 실적 발표

HUTCHMED (China) Limited의 실적 발표 예정일은 Jul 30, 2017, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2일 전 · Proactive

HUTCHMED shares rise as lung cancer drug trial hits key targets

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung ...

2주 전 · GuruFocus.com

HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and ...

HUTCHMED (China) Ltd (HCM) reports robust China product sales and global expansion, while advancing its novel ATTC pipeline and maintaining a profitable outlook.

2주 전 · MarketBeat

HUTCHMED H1 Earnings Call Highlights

HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported r...

2개월 전 · Insider Monkey

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks. TheFly reported on May 28 that Mo...

3개월 전 · MarketBeat

HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference

HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at th...

2 페이지 중 1

HUTCHMED (China) Limited (HCM)